Expanding contraceptive choices: lunelle monthly contraceptive injection.
Contraceptive options for women have expanded with the FDA approval of a monthly injectable contraceptive. Containing a progestin and estrogen (25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate; Lunelle/Lunella; Pharmacia and Upjohn), this novel once-a-month injection is characterized by the convenience and contraceptive efficacy of long-term reversible methods and the cycle control, return to fertility and side-effect profiles common to low-dose oral contraceptives. The association of these desirable attributes may increase the likelihood that a woman's chosen method will be used consistently and correctly to reduce the frequency of unintended pregnancy.
Shulman
L P
LP
Department of Obstetrics and Gynecology, University of Illinois at Chicago, 60612-7313, USA.
D000293:Adolescent; D000328:Adult; D003267:Contraception / Q000379:methods; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D008875:Middle Aged; D017060:Patient Satisfaction; D011247:Pregnancy; D014481:United States
D003271:Contraceptive Agents, Female; C403500:Lunelle; D004958:Estradiol; D017258:Medroxyprogesterone Acetate